[1] [1] NEWELL L F, COOK R J. Advances in acute myeloid leukemia ［J］. BMJ (Clinical Research Edition), 2021, 375: n2026.

[2] [2] ESTEY E H. Acute myeloid leukemia: 2019 update on risk-stratification and management ［J］. American Journal of Hematology, 2018, 93(10): 1267-1291.

[3] [3] THOL F, GANSER A. Treatment of relapsed acute myeloid leukemia ［J］. Current Treatment Options in Oncology, 2020, 21(8): 66.

[4] [4] CICIARELLO M, CORRADI G, FORTE D, et al. Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: tangle or chance? ［J］. Cancers (Basel), 2021, 13(21): 5319.

[5] [5] WU T, DAI Y. Tumor microenvironment and therapeutic response ［J］. Cancer Letters, 2017, 387: 61-68.

[6] [6] WANG H, WU X, CHEN Y. Stromal-immune score-based gene signature: a prognosis stratification tool in gastric cancer ［J］. Frontiers in Oncology, 2019, 9: 1212.

[7] [7] NEWMAN A M, STEEN C B, LIU C L, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry ［J］. Nature Biotechnology, 2019, 37(7): 773-782.

[8] [8] FORTE D, GARCIA-FERNANDEZ M, SANCHEZ-AGUILERA A, et al. Bone barrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy ［J］. Cell Metabolism, 2020, 32(5): 829-843.e9.

[9] [9] MULHERKAR N, SCADDEN D T. What is the role of the bone marrow microenvironment in AML? ［J］. Best Practice & Research Clinical Haematology, 2021, 34(4): 101328.

[10] [10] PRADA-ARISMENDY J, ARROYAVE J C, ROTHLISBERGER S. Molecular biomarkers in acute myeloid leukemia ［J］. Blood Reviews, 2017, 31(1): 63-76.

[11] [11] JOHNSTONE C N, PATTISON A D, HARRISON P F, et al. FGF13 promotes metastasis of triple-negative breast cancer ［J］. International Journal of Cancer, 2020, 147(1): 230-243.

[12] [12] WU Y, CONG L, CHEN W, et al. lncRNA LINC00963 downregulation regulates colorectal cancer tumorigenesis and progression via the miR10b/FGF13 axis ［J］. Molecular Medicine Reports, 2021, 23(3): 211.

[13] [13] LIU T, WU H, QI J, et al. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma ［J］. Cancer Medicine, 2020, 9(20): 7440-7452.

[14] [14] RUSSO V, KLEIN T, LIM D J, et al. Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction ［J］. Scientific Reports, 2018, 8(1): 9690.

[15] [15] GOFF S L, DANFORTH D N. The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer ［J］. Clinical Breast Cancer, 2021, 21(1): e63-e73.

[16] [16] PATNAIK M M. The importance of FLT3 mutational analysis in acute myeloid leukemia ［J］. Leukemia & Lymphoma, 2018, 59(10): 2273-2286.

[17] [17] BURCHERT A. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia ［J］. Haematologica, 2021, 106(3): 664-670.

[18] [18] THOMAS C M, CAMPBELL P. FLT3 inhibitors in acute myeloid leukemia: current and future ［J］. Journal of Oncology Pharmacy Oractice, 2019, 25(1): 163-171.

[19] [19] BENNETT C, LAWRENCE M, GUERRERO J A, et al. CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia ［J］. Blood, 2022, 139(14): 2227-2239.

[20] [20] PADELLA A, SIMONETTI G, PACIELLO G, et al. Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia ［J］. Cancers, 2019, 11(12): 1951.

[21] [21] PICARD E, VERSCHOOR C P, MA G W, et al. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer ［J］. Frontiers in Immunology, 2020, 11: 369.

[22] [22] PAN J H, ZHOU H, COOPER L, et al. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers ［J］. Frontiers in Immunology, 2019, 10: 6.

[23] [23] CHEN B, KHODADOUST M S, LIU C L, et al. Profiling tumor infiltrating immune cells with CIBERSORT ［J］. Methods in Molecular Biology (Clifton, NJ), 2018, 1711: 243-259.

[24] [24] CRAVEN K E, GOKMEN-POLAR Y, BADVE S S. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer ［J］. Scientific Reports, 2021, 11(1): 4691.

[25] [25] YE L, ZHANG T, KANG Z, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer ［J］. Frontiers in Immunology, 2019, 10: 2368.

[26] [26] LI B, CHAN H L, CHEN P. Immune checkpoint inhibitors: basics and challenges ［J］. Current Medicinal Chemistry, 2019, 26(17): 3009-3025.

[27] [27] TOPALIAN S L, TAUBE J M, ANDERS R A, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy ［J］. Nature Reviews Cancer, 2016, 16(5): 275-287.

[28] [28] RUFFO E, WU R C, BRUNO T C, et al. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor ［J］. Seminars in Immunology, 2019, 42: 101305.